Search Results
Feb 05, 2026, 04:09 ET HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026
phagocytosis while minimizing hematologic toxicities.HCB301: A first-in-class multi-specific candidate targeting the CD47/SIRPα, PD-1/PD-L1, and TGFb pathways to overcome the immunosuppressive tumor microenvironment (TME)."The concentration of oral and poster presentations
More news about: HanchorBio Inc.
Feb 05, 2026, 00:00 ET Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism
Scientific Inc., has published a study in Nature that pinpoints the core functional circuit underlying Parkinson's disease (PD). The findings redefine the biological mechanism of PD and provide a scientific basis for developing precision neural circuit stimulation strategies for treating the condition.
More news about: Galaxy Brain Scientific Inc.
Feb 04, 2026, 07:48 ET AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination
More news about: AbbVie
Feb 03, 2026, 21:58 ET FICG Highlights Advanced Packaging Integration for Optical Transceivers at APE 2026
transceivers progress into the 800G and 1.6T era, FICG has introduced flip-chip packaging into high-speed optical transceiver manufacturing, while advancing PIC/PD integration and lower-power design directions to help customers improve interconnect bandwidth, energy efficiency, and system scalability. FICG has established
More news about: FIC Global, Inc.
Feb 03, 2026, 16:01 ET AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
DeLLphi-303, a Phase 1b study of IMDELLTRA in combination with a programmed cell death protein ligand-1 (PD-L1) inhibitor, carboplatin and etoposide or separately in combination with a PD-L1 inhibitor alone, is ongoing in patients with first-line ES-SCLC.DeLLphi-305, a Phase 3 study of IMDELLTRA
More news about: Amgen
Feb 03, 2026, 14:47 ET APhA‑backed reforms pass Congress--Covering pharmacist care must be next
produce formal reports evaluating PBM arrangements across the supply chain and within Prescription Drug Plans and Medicare Advantage–Prescription Drug (MA PD) plans, including how these agreements affect both pharmacy reimbursement and beneficiary out-of-pocket spending."Congress has taken an important
More news about: American Pharmacists Association
Feb 03, 2026, 06:45 ET Canada Nickel Announces Filing of NI 43-101 Technical Reports for Previously Announced Initial Resources, Midlothian and Bannockburn Projects
Mineral Resource Estimate and Technical Report for the Midlothian Ni-Co-Pd-Pt Deposit, Midlothian Nickel Sulphide Project", and "National Instrument 43-101 Initial Mineral Resource Estimate and Technical Report for the Bannockburn Ni-Co-Pd-Pt Deposit, Bannockburn Nickel Sulphide Project" The Reports were prepared
More news about: Canada Nickel Company Inc.
Feb 02, 2026, 17:31 ET TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
malignancies.AstraZeneca, Compugen, and Daiichi Sankyo's Rilvegostomig is a bispecific antibody that simultaneously targets PD-1 and TIGIT. By concurrently blocking PD-1 interactions with PD-L1/PD-L2 and TIGIT interactions with CD112/CD155, it reinvigorates T-cell activity and boosts CD226-mediated signaling in
More news about: DelveInsight Business Research, LLP
Feb 02, 2026, 08:25 ET Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio
clinical study of BT-409, a potentially best-in-class, brain-permeable NLRP3 inhibitor being developed for multiple sclerosis (MS), Parkinson's disease (PD), and other neuroinflammatory indications.
More news about: Mwyngil Therapeutics
Feb 02, 2026, 07:45 ET TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
serious dose limiting toxicities in addition to demonstrating that patients refractory to checkpoint inhibitor therapy (anti-PD1) experienced clinical benefit upon subsequent anti-PD1 based treatment.Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences, said, "Our current
More news about: TuHURA Biosciences, Inc.
Jan 30, 2026, 08:00 ET Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models and patient-derived
More news about: Kazia Therapeutics Limited
Jan 29, 2026, 08:30 ET Transforming Pediatric Rare Disease Trials Through Modeling and Simulation, and Site Networks, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into how model-informed drug development uses early PK/PD data, extrapolation and simulation to enable earlier, regulator-ready pediatric dose selection with fewer patients. Attendees will learn why pediatric rare disease trials require adapted clinical operations
More news about: Xtalks
Jan 29, 2026, 07:05 ET XTI Aerospace's Drone Nerds Business Adds New DJI RS 5 Gimbal Stabilizer to Portfolio
axis locks streamline setup, transport, and storage.Power enhancements include a one-hour full charge capability when used with a compatible 65W PD charger and the DJI RS BG33 Battery Grip. The RS 5 is also compatible with the DJI RS BG70 High-Capacity Battery Grip.The electronic briefcase
More news about: XTI Aerospace, Inc.
Jan 28, 2026, 21:21 ET QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
abstract submission about the Phase Ib/II Clinical Data of its Q-1802 program. The report（Abstract #537934）is titled "PhaseⅠ/Ⅱ Trial of Anti-CLDN18.2/PD-L1 Recombinant Humanized Bispecific Antibody Q-1802 Plus XELOX in Treatment-Naive CLDN18.2-Positive Advanced GC/GEJ"The authors, Dr. Gong et al,
More news about: QureBio Ltd.
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
cancer immunotherapy, for the treatment of patients with human papillomavirus type 16 positive head and neck squamous cell carcinoma (HNSCC) expressing PD-L1. The designation was granted based on preliminary safety and efficacy data from the ongoing pivotal Phase 2/3 AHEAD-MERIT clinical trial evaluating
More news about: USA News Group
Jan 28, 2026, 07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease
transporting therapeutic agents across the blood–brain barrier (BBB) and precisely directing them to impacted neural regions implicated in Parkinson's disease (PD). This landmark research has been published in the leading international publication Journal of Nanobiotechnology. αDAT-EV: The World's First
More news about: China Medical University Hospital
Jan 27, 2026, 10:50 ET Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
immunotherapy pipeline focuses on enhancing innate and adaptive immune responses to enable robust antitumor activity in combination with the approved PD-1 inhibitor LOQTORZI.Source:
More news about: Equity Insider
Jan 27, 2026, 09:00 ET Parkinson's Foundation Launches Nurse Practitioner Fellowship Program in Collaboration with Emory University
diagnosing, managing and treating the complex motor and non-motor symptoms of PD. Recipients will work closely with patients, families and interdisciplinary care teams to optimize treatment and support quality of life for people living with PD. "As one of the leading medical centers in the United States,
More news about: Parkinson's Foundation
Jan 27, 2026, 09:00 ET Aurzen Super Bowl Projector Deals: Big-Screen Viewing for Less
USOffering the biggest discount in the lineup, the BOOM air delivers punchy audio in a portable design without the need for extra speakers. USB-C and 65W PD power bank support enable outdoor and on-the-go viewing.
More news about: Aurzen Official
Jan 27, 2026, 08:37 ET Dual Platform Options for Critical Single-Use Freeze and Thaw Operations from Meissner
single–use solution options for secure freeze and thaw unit operations. Delivering unmatched security at every scale, from small process development (PD) through commercial scale production, Meissner's single-use freeze and thaw systems are designed to reduce risk at every processing step, from fill and
More news about: Meissner Corporation
Jan 27, 2026, 08:00 ET Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
standard-of-care first-line regimen) or Olaparib (advanced breast cancer patients with BRCA mutations). Eligibility for the pembrolizumab-containing cohort required PD-L1–positive disease (CPS ≥10), consistent with standard-of-care practice in metastatic TNBC.Patient 1 – Partial ResponseA 61-year-old
More news about: Kazia Therapeutics Limited
Jan 26, 2026, 10:00 ET Blacksmith Medicines and Collaborators to Present at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Collaborator Poster Details: Title: "Utilizing a Simultaneous Neutropenic Thigh and Hematogenous Pyelonephritis Mouse Model to Determine PK/PD Efficacy of a Novel LpxC Inhibitor FG-2101"Lead Author & Affiliation: David Andes, Ph.D., Chief of the Division of Infectious Disease
More news about: Blacksmith Medicines
Jan 26, 2026, 02:00 ET HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is
More news about: HanchorBio Inc.
Jan 23, 2026, 12:22 ET Brazil Achieves a Historic Milestone: Blau Farmacêutica Fully Develops One of the World's Most Advanced Biosimilars Immunotherapies
For the first time, a Brazilian company has achieved full end-to-end development of a high-complexity monoclonal antibody (anti-PD-1), covering drug substance and drug product. All stages — including cell line development, bioprocess development, biological characterization, comparability
More news about: Blau Farmacêutica
Jan 22, 2026, 23:40 ET 晶泰科技賦能萊芒生物取得細胞療法重大成果，以1‰劑量CAR-T實現多位系統性紅斑狼瘡完全緩解出院
46.5 億美元，並將以 22.2% 的年複合增長率在 2030 年達到 159.7 億美元。當前 CAR-T 療法在血液瘤領域雖已取得一定成效，但仍面臨著復發率高、實體瘤響應有限、成本高昂三大挑戰，其根源在於 T 細胞在持續抗腫瘤過程中易進入 「終末耗竭」 狀態，喪失增殖與殺傷能力，並對 PD-1/PD-L1 等免疫檢查點抑制劑無響應。萊芒生物是晶泰科技於 2022 年孵化投資的創新企業，其創始團隊來自全球頂尖理工院校瑞士洛桑聯邦理工學院（EPFL）。通過與晶泰科技的深度研發合作，萊芒生物開發了其獨有的 META 10 與 META 10-AI 兩大 AI+代謝重編程技術平台，實現對耗竭
More news about: 晶泰科技